{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T19:03:30Z","timestamp":1777143810842,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jbspin.2024.105799","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:51:50Z","timestamp":1730271110000},"page":"105799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hydroxychloroquine and Sj\u00f6gren's disease: current evidences for its use"],"prefix":"10.1016","volume":"92","author":[{"given":"Marlon J.","family":"Sandino-Berm\u00fadez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7958-0391","authenticated-orcid":false,"given":"Gabriela","family":"Hern\u00e1ndez-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2024.105799_bib0260","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.intimp.2015.03.027","article-title":"How are we treating our systemic patients with primary Sj\u00f6gren syndrome? Analysis of 1120 patients","volume":"27","author":"Gheitasi","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0265","first-page":"182","article-title":"Do antimalarials protect against damage accrual in primary Sj\u00f6gren's syndrome? Results from a Latin-American retrospective cohort","volume":"36","author":"Hern\u00e1ndez-Molina","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0275","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.revmed.2023.07.001","article-title":"French national diagnostic and care protocol for Sj\u00f6gren's disease","volume":"44","author":"Devauchelle-Pensec","year":"2023","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jbspin.2024.105799_bib0280","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2024.105799_bib0285","first-page":"keae218","article-title":"Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sj\u00f6gren disease","author":"Price","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105799_bib0290","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.rbr.2015.07.004","article-title":"Recommendations for the treatment of Sj\u00f6grens syndrome","volume":"55","author":"Valim","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0295","doi-asserted-by":"crossref","first-page":"e12476","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jbspin.2024.105799_bib0300","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.42540","article-title":"Lysosome-associated membrane protein 3 induces lysosome-dependent cell death by impairing autophagic caspase 8 degradation in the salivary glands of individuals with Sj\u00f6gren's disease","volume":"75","author":"Nakamura","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0305","doi-asserted-by":"crossref","first-page":"e0282227","DOI":"10.1371\/journal.pone.0282227","article-title":"Salivary gland LAMP3\u00a0mRNA expression is a possible predictive marker in the response to hydroxychloroquine in Sj\u00f6gren's disease","volume":"18","author":"Nakamura","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2024.105799_bib0310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","article-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren's syndrome in the JOQUER randomized trial","volume":"59","author":"Bodewes","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105799_bib0315","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/annrheumdis-2012-202552","article-title":"MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sj\u00f6gren's syndrome","volume":"73","author":"Maria","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0320","doi-asserted-by":"crossref","first-page":"e002979","DOI":"10.1136\/rmdopen-2023-002979","article-title":"Leflunomide\/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sj\u00f6gren's syndrome that show potential to predict and monitor clinical response","volume":"9","author":"Hamkour","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105799_bib0325","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/1744666X.2019.1624527","article-title":"Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sj\u00f6grens\u2019 syndrome","volume":"15","author":"van der Heijden","year":"2019","journal-title":"Exp Rev Clinical Immunol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0330","first-page":"229","article-title":"Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sj\u00f6gren's syndrome","volume":"11","author":"Mumcu","year":"2013","journal-title":"Oral Health Prev Dent"},{"key":"10.1016\/j.jbspin.2024.105799_bib0335","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","article-title":"Hydroxychloroquine improves dry eye symptoms of patients with primary Sj\u00f6gren's syndrome","volume":"31","author":"Yavuz","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2024.105799_bib0340","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/rheumatology\/keh506","article-title":"Hydroxychloroquine therapy in patients with primary Sj\u00f6gren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase","volume":"44","author":"Dawson","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105799_bib0345","doi-asserted-by":"crossref","first-page":"111352","DOI":"10.1016\/j.celrep.2022.111352","article-title":"Microbiota dysbiosis in primary Sj\u00f6gren's syndrome and the ameliorative effect of hydroxychloroquine","volume":"40","author":"Wang","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jbspin.2024.105799_bib0350","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.tripleo.2010.02.032","article-title":"Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sj\u00f6gren patients: a prospective sample study","volume":"110","author":"\u00c7ankaya","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0355","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/rheumatology\/kep104","article-title":"Treatment of sicca symptoms with hydroxychloroquine in patients with Sj\u00f6gren's syndrome","volume":"48","author":"Rihl","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105799_bib0360","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/0961203396005001081","article-title":"Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2024.105799_bib0365","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00296-024-05545-0","article-title":"Assessment of hydroxychloroquine blood levels in Sj\u00f6gren's disease patients: drug adherence and clinical associations","volume":"44","author":"Pasoto","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2024.105799_bib0370","doi-asserted-by":"crossref","first-page":"e1044","DOI":"10.1002\/iid3.1044","article-title":"Combined use of total glucosides of paeony and hydroxychloroquine in primary Sj\u00f6gren's syndrome: A systematic review","volume":"11","author":"Zhang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0375","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","article-title":"Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren's syndrome: A double-blind randomized control study","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jbspin.2024.105799_bib0380","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: A two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of Hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2024.105799_bib0390","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-021-04927-y","article-title":"Revisiting the JOQUER trial: stratification of primary Sj\u00f6gren's syndrome and the clinical and interferon response to hydroxychloroquine","volume":"41","author":"Collins","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2024.105799_bib0395","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide-hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomized clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0400","first-page":"656","article-title":"Safety and efficacy of oral hydroxychloroquine in the treatment of ophthalmic disease associated with Sj\u00f6gren's syndrome","volume":"29","author":"Fang","year":"2023","journal-title":"Altern Ther Health Med"},{"key":"10.1016\/j.jbspin.2024.105799_bib0405","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12891-017-1543-z","article-title":"Is hydroxychloroquine effective in treating primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jbspin.2024.105799_bib0410","doi-asserted-by":"crossref","first-page":"693796","DOI":"10.3389\/fphar.2021.693796","article-title":"The efficiency of hydroxychloroquine for the treatment of primary Sj\u00f6gren's syndrome: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0415","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s10067-017-3822-3","article-title":"Primary Sj\u00f6gren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy","volume":"36","author":"Demarchi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.autrev.2018.06.015","article-title":"Arthritis in primary Sj\u00f6gren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study","volume":"18","author":"Mirouse","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2024.105799_bib0425","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/1346-8138.16045","article-title":"Efficacy of hydroxychloroquine for treating annular erythema associated with Sj\u00f6gren's syndrome","volume":"48","author":"Arakawa","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0430","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s10787-021-00887-8","article-title":"Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases","volume":"29","author":"Onmaz","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jbspin.2024.105799_bib0435","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/ard.58.4.253","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: its effect on salivary and serum inflammatory markers","volume":"58","author":"Tishler","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0440","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12026-016-8888-5","article-title":"Obstetric and perinatal outcome in anti-Ro\/SSA-positive pregnant women: a prospective cohort study","volume":"65","author":"Martinez-Sanchez","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.jbspin.2024.105799_bib0445","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","article-title":"Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA\/Ro-positive mothers","volume":"76","author":"Izmirly","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0450","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/rheumatology\/kead379","article-title":"Divergence of patients-reported xerostomia and oral health in primary Sj\u00f6gren's syndrome and the possible role of hydroxychloroquine","volume":"63","author":"Alunno","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2024.105799_bib0455","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.21037\/apm-20-1380","article-title":"Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sj\u00f6gren's syndrome: a real-world study","volume":"9","author":"Guan","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jbspin.2024.105799_bib0460","doi-asserted-by":"crossref","first-page":"902","DOI":"10.3899\/jrheum.131156","article-title":"Effect of hydroxychloroquine on the lipid profile of patients with Sj\u00f6gren syndrome","volume":"41","author":"Migkos","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0465","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/qjmed\/hcz112","article-title":"Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sj\u00f6gren syndrome","volume":"112","author":"Chen","year":"2019","journal-title":"QJM"},{"key":"10.1016\/j.jbspin.2024.105799_bib0470","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/1756-185X.14400","article-title":"Sj\u00f6gren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes","volume":"25","author":"Su","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0475","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.3390\/jcm9113469","article-title":"Cardiovascular protection of hydroxychloroquine in patients with Sj\u00f6gren's syndrome","volume":"9","author":"Yang","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2024.105799_bib0480","doi-asserted-by":"crossref","first-page":"80461","DOI":"10.18632\/oncotarget.19057","article-title":"Hydroxychloroquine and risk of cancer in patients with primary Sj\u00f6gren syndrome: propensity score matched landmark analysis","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbspin.2024.105799_bib0485","first-page":"S177","article-title":"Use and withdrawal of immunosuppressors in primary Sj\u00f6gren's syndrome","volume":"36","author":"Torres-Ruiz","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0490","first-page":"160","article-title":"Discontinuation rates and timing of antimalarial drugs in primary Sj\u00f6gren's syndrome","volume":"31","author":"Baldini","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0495","doi-asserted-by":"crossref","first-page":"631869","DOI":"10.3389\/fimmu.2021.631869","article-title":"Hydroxychloroquine does not increase the risk of cardiac arrhythmia in common rheumatic diseases: a nationwide population-based cohort study","volume":"12","author":"Lo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0500","doi-asserted-by":"crossref","DOI":"10.1177\/20406223231164498","article-title":"Ocular microvascular alteration in Sj\u00f6gren's syndrome treated with hydroxychloroquine: an OCTA clinical study","volume":"14","author":"Yu","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jbspin.2024.105799_bib0505","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/1744666X.2023.2234641","article-title":"Why do drug treatments fail in Sj\u00f6gren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy","volume":"19","author":"Arends","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2024.105799_bib0510","unstructured":"New Clinical end-points in patients with Primary Sj\u00f6gren's Syndrome (NECESSITY). https:\/\/clinicaltrials.gov\/study\/NCT05113004?cond=Sjogren%27s%20Syndrome&intr=Leflunomide&rank=1 [accessed 2023-03-01]."}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:03:05Z","timestamp":1737630185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X24001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1297319X24001106"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105799","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxychloroquine and Sj\u00f6gren's disease: current evidences for its use","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\ufffdt\ufffd Fran\ufffdaise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105799"}}